<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868189</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2018-01/SC-01</org_study_id>
    <nct_id>NCT03868189</nct_id>
  </id_info>
  <brief_title>Interest of Ultrasonography in Electroneuromyography: Single-blind Randomised Controlled Clinical Trial</brief_title>
  <acronym>US ENMG</acronym>
  <official_title>Interest of Ultrasonography in Electroneuromyography: Single-blind Randomised Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Echo-nerve tracking during an electroneuromyographic (ENMG) examination by identifying the&#xD;
      optimal stimulation site would reduce the stimulation intensities delivered to the patient&#xD;
      and thus improve the tolerance of this examination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Actual">November 11, 2020</completion_date>
  <primary_completion_date type="Actual">January 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Supra-maximal stimulation intensity delivered by stimulation site on sensory nerves</measure>
    <time_frame>Day 0</time_frame>
    <description>unit : milliampere (mA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Supra-maximal stimulation intensity delivered by stimulation site on the motor nerves</measure>
    <time_frame>Day 0</time_frame>
    <description>unit : mA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity Amplitude per collection site</measure>
    <time_frame>Day 0</time_frame>
    <description>unit : microvolts (uV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Amplitude per collection site</measure>
    <time_frame>Day 0</time_frame>
    <description>unit : Millivolts (mV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of explored muscles</measure>
    <time_frame>Day 0</time_frame>
    <description>unit : number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of explored unusual muscles</measure>
    <time_frame>Day 0</time_frame>
    <description>unit : number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall examination time between the beginning of the stimulation and the end of the myography examination</measure>
    <time_frame>Day 0</time_frame>
    <description>unit : minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average time per explored site (total duration divided by the number of explored nerves and muscles)</measure>
    <time_frame>Day 0</time_frame>
    <description>unit : minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of satisfaction</measure>
    <time_frame>Day 0</time_frame>
    <description>Likert scale that range from 1 (&quot;not satisfied at all &quot;) to 4 (&quot;totally satisfied&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of felt pain</measure>
    <time_frame>Day 0</time_frame>
    <description>Analogical visual scale of pain from 1 (no pain) to 100 (maximum pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Electromyoneurography</condition>
  <arm_group>
    <arm_group_label>electroneuromyography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electroneuromyography with ultrasound</intervention_name>
    <description>Patients whose electroneuromyography examination will be performed using an ultrasound</description>
    <arm_group_label>electroneuromyography</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electroneuromyography without ultrasound</intervention_name>
    <description>Patients whose electroneuromyography examination will be performed without ultrasound (fake tracking)</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient requiring an electroneuromyogram whose indication allows the application of a&#xD;
             standard protocol of examination.&#xD;
&#xD;
          -  Patient that has given his/her free and informed consent.&#xD;
&#xD;
          -  Patient that signed the consent form.&#xD;
&#xD;
          -  Patient with an health insurance plan.&#xD;
&#xD;
          -  The patient is at least 18 years old (≥).&#xD;
&#xD;
          -  he patient is under 80 years old (≤).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with symptoms of neuropathy during the screening.&#xD;
&#xD;
          -  Patient whose Neurological severity score (NSS) score is ≥ 3.&#xD;
&#xD;
          -  Patient whose neurological examination is abnormal and suggestive of neuropathy.&#xD;
&#xD;
          -  Patient presenting a pathology that could cause neuropathy (e.g. diabetes, renal&#xD;
             failure, etc.).&#xD;
&#xD;
          -  Patient already participating in a category 1 research study (Jardé law).&#xD;
&#xD;
          -  Patient in an exclusion period determined by another study.&#xD;
&#xD;
          -  Patient under the protection of justice, under guardianship or under curatorship.&#xD;
&#xD;
          -  Patient refusing to sign the consent form.&#xD;
&#xD;
          -  Patient for which it is impossible to provide information about the study.&#xD;
&#xD;
          -  Pregnant patient, parturient, or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah COUDRAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nîmes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nîmes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

